Breast cancer claims approximately 670,000 lives each year, with breast cancer being the most common cancer in women in 157 out of 185 countries in 2022, according to data from the World Health Organization (WHO). Over 2 million women are diagnosed with breast cancer annually, highlighting the importance of early detection and targeted treatment. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, in combination with hormone therapy for the early-stage breast cancer treatment. This approval provides a new option for patients concerned about cancer recurrence. Kisqali works as a selective cyclin-dependent kinase inhibitor, targeting proteins that promote cancer cell growth. It is administered orally as a pill for three weeks followed by a one-week break, to be continued for three years. The recommended daily dose is 400 mg, which can be taken with or without food.Kisqali: Side effects

Common side effects linked to Kisqali medication include low white blood cell count or neutropenia. Neutropenia arises from reduced levels of neutrophils in the bloodstream, which are crucial for combating infections in the body. Kisqali may also cause liver-related problems and interstitial lung disease/pneumonitis.

Breast Cancer: Signs of the disease that should never be overlooked